MGNX - MacroGenics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.23
-0.41 (-2.46%)
At close: 4:00PM EDT

16.23 0.00 (0.00%)
After hours: 4:42PM EDT

Stock chart is not supported by your current browser
Previous Close16.64
Open16.59
Bid16.22 x 800
Ask16.41 x 900
Day's Range16.13 - 16.68
52 Week Range9.87 - 32.32
Volume519,834
Avg. Volume841,007
Market Cap792.115M
Beta (3Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-3.87
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.70
Trade prices are not sourced from all markets
  • TheStreet.com12 days ago

    2 Small Biotechs With Sagging Shares but Promising Prospects

    As discussed in my column on Monday, small biotechs that need to raise money over the next 12 months as they ramp up sales on recently approved products have been particularly hit hard. Developmental concerns with no approved products are doing much better provided they have adequate cash runways. Data support what should be a successful New Drug Application (NDA) in the near future, but the information wasn't as overwhelming positive as some investors evidently hoped for as MacroGenics shares saw some profit taking in the days after the event.

  • Implied Volatility Surging for MacroGenics (MGNX) Stock Options
    Zacks18 days ago

    Implied Volatility Surging for MacroGenics (MGNX) Stock Options

    Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

  • GlobeNewswire25 days ago

    MacroGenics to Participate in Jefferies Healthcare Conference

    Rockville, MD, May 30, 2019 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • GlobeNewswire27 days ago

    MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio webcast on Tuesday, June 4 at 1:30 p.m. CT (2:30 p.m. ET). MacroGenics management will be joined by external guest presenters to review the margetuximab Phase 3 SOPHIA study presentation at the American Society of Clinical Oncology (ASCO) annual meeting and discuss ongoing and future clinical development plans for margetuximab, an Fc-optimized anti-HER2 antibody. To participate in the MacroGenics ASCO 2019 Conference Call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and provide the Conference ID: 9959793.

  • 3 Cancer Treatment Stocks to Buy Right Now
    Motley Foollast month

    3 Cancer Treatment Stocks to Buy Right Now

    These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.

  • Is MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Overpaid Relative To Its Peers?
    Simply Wall St.last month

    Is MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Overpaid Relative To Its Peers?

    In 2001 Scott Koenig was appointed CEO of MacroGenics, Inc. (NASDAQ:MGNX). This report will, first, examine the CEO...

  • Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
    Investor's Business Dailylast month

    Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting

    Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.

  • Why MacroGenics, Inc. Stock Is Heating Up Today
    Motley Foollast month

    Why MacroGenics, Inc. Stock Is Heating Up Today

    MacroGenics shares jumped in response to another major clinical update today.

  • Benzingalast month

    The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...

  • Microsoft, Amazon, and More: Why These Stocks Are Trending
    Insider Monkeylast month

    Microsoft, Amazon, and More: Why These Stocks Are Trending

    It's getting close to 13F filing season and several stocks such as Amazon and JPMorgan are in the spotlight because of it. Furthermore, Microsoft is also in the spotlight due to an unrelated issue concerning some of its software. Without further ado, let's analyze why traders are watching each stock and how the smart money […]

  • GlobeNewswirelast month

    MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced additional details of the results from the Phase 3 SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. Margetuximab is an investigational, immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc Optimization technology platform.

  • 3 Stocks With Big News Coming at ASCO 2019
    Motley Foollast month

    3 Stocks With Big News Coming at ASCO 2019

    These cancer drug developers could report market-moving news soon.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MGNX earnings conference call or presentation 26-Feb-19 9:30pm GMT

    Q4 2018 MacroGenics Inc Earnings Call

  • Macrogenics Inc (MGNX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Macrogenics Inc (MGNX) Q1 2019 Earnings Call Transcript

    MGNX earnings call for the period ending March 31, 2019.

  • MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

    MacroGenics (MGNX) delivered earnings and revenue surprises of -4.21% and -15.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    MacroGenics: 1Q Earnings Snapshot

    On a per-share basis, the Rockville, Maryland-based company said it had a loss of 99 cents. The results fell short of Wall Street expectations. The average estimate of eight analysts surveyed by Zacks ...

  • GlobeNewswire2 months ago

    MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results

    ROCKVILLE, Md., May 01, 2019 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • Md. biotech files to go public in up to $92M offering
    American City Business Journals2 months ago

    Md. biotech files to go public in up to $92M offering

    NextCure Inc., a Beltsville biotech with one anticancer drug in clinical testing and several local biotech veterans in its leadership ranks, has filed to go public three years after its founding. The company, which has applied to trade on the Nasdaq Global Market under the ticker symbol "NXTC," plans to offer 5 million shares to the public, with up to 750,000 additional shares available to its underwriters. It estimates an offering price of $14 to $16 per share, bringing a potential total haul to $80.5 million to $92 million if all shares are sold in the initial public offering.

  • GlobeNewswire2 months ago

    MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2019 after the market closes on Wednesday, May 1, 2019. MacroGenics will host a conference call to discuss the financial results and recent corporate developments on Wednesday, May 1, 2019 at 4:30 p.m. ET. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm.

  • GlobeNewswire3 months ago

    MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the presentation of preclinical and clinical data at the American Association for Cancer Research Annual Meeting 2019 (AACR) held in Atlanta, Georgia. The posters presented at AACR by MacroGenics and its collaborators are listed below and available for download from the Events & Presentations page in the Investors section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

  • TheStreet.com3 months ago

    3 Promising Small Biotech Stocks to Watch

    In Monday's column, we recapped the first quarter for the overall market as well as the biotech sector. It will be a quarterly performance that we are unlikely to match for some time. As noted then, it presented mid-stage data at the American Association for Cancer Research conference in Atlanta this week.

  • GlobeNewswire3 months ago

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, April 02, 2019 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • Introducing MacroGenics (NASDAQ:MGNX), The Stock That Dropped 20% In The Last Five Years
    Simply Wall St.3 months ago

    Introducing MacroGenics (NASDAQ:MGNX), The Stock That Dropped 20% In The Last Five Years

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is doubtless a positive to see that the MacroGenics, Inc. (NASDAQ:MGNX) share price has gained some 46% in the last thr...

  • Why MacroGenics Stock Rocketed 70.5% Higher in February
    Motley Fool4 months ago

    Why MacroGenics Stock Rocketed 70.5% Higher in February

    Positive results for its breast cancer drug candidate lit a fire under this small-cap biotech.